Work

A Phase II Study of MLN8237 (Alisertib) Alone and in Combination with Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (NHL)

Year: 2014

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v124.21.3082.3082

Authors: Kami J. Maddocks, Jonathon B. Cohen, Beth Christian, Joseph M Flynn, Samantha M. Jaglowski, Kristie A. Blum

Institutions: The Ohio State University, Winship Cancer Institute, The Ohio State University Wexner Medical Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2588656890

FWCI: 0.829

Cites:

Cited by: 3

Related to: 10